TRCT
PAVM icon

Tower Research Capital (TRC)’s PAVmed PAVM Stock Holding History

Tower Research Capital (TRC)’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.31K Buy
622
+476
+326% +$4.5K ﹤0.01% 4062
2025
Q4 		$964 Hold
146
– – ﹤0.01% 4787
2025
Q3 		$1.89K Sell
146
-4
-3% -$59 ﹤0.01% 4715
2025
Q2 		$2.69K Hold
150
– – ﹤0.01% 4605
2025
Q1 		$3.25K Sell
150
-1
-0.7% -$21 ﹤0.01% 4446
2024
Q4 		$2.84K Buy
151
+27
+22% +$798 ﹤0.01% 4765
2024
Q3 		$4.57K Sell
124
-199
-62% -$6.1K ﹤0.01% 4499
2024
Q2 		$7.91K Buy
323
+241
+294% +$12K ﹤0.01% 4412
2024
Q1 		$5.26K Sell
82
-44
-35% -$3.33K ﹤0.01% 4567
2023
Q4 		$15.5K Buy
126
+11
+10% +$1.3K ﹤0.01% 3821
2023
Q3 		$15.3K Buy
115
+58
+102% +$8.99K ﹤0.01% 3625
2023
Q2 		$10.4K Sell
57
-27
-32% -$5.4K ﹤0.01% 4120
2023
Q1 		$14K Buy
84
+45
+115% +$9.47K ﹤0.01% 3903
2022
Q4 		$9K Sell
39
-15
-28% -$5.66K ﹤0.01% 4235
2022
Q3 		$21K Buy
+54
New +$30.6K ﹤0.01% 3900
2022
Q2 		– Sell
-50
Closed -$24.2K – 6409
2022
Q1 		$29K Buy
50
+17
+52% +$12.6K ﹤0.01% 3194
2021
Q4 		$36K Buy
33
+23
+230% +$50K ﹤0.01% 3052
2021
Q3 		$38K Sell
10
-2
-17% -$6.31K ﹤0.01% 3181
2021
Q2 		$34K Sell
12
-52
-81% -$123K ﹤0.01% 3356
2021
Q1 		$127K Buy
64
+41
+178% +$61.7K ﹤0.01% 2392
2020
Q4 		$22K Sell
23
-54
-70% -$46.2K ﹤0.01% 3809
2020
Q3 		$62K Buy
77
+22
+40% +$19.6K ﹤0.01% 3445
2020
Q2 		$53K Buy
+55
New +$55K ﹤0.01% 2998
2017
Q2 		– Sell
-2
Closed -$5K – 3240
2017
Q1 		$5K Hold
2
– – ﹤0.01% 2213
2016
Q4 		$5K Buy
2
+1
+100% +$4.19K ﹤0.01% 3051
2016
Q3 		$3K Buy
+1
New +$6.36K ﹤0.01% 2875

Other funds holding PAVM

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Tower Research Capital (TRC)'s PAVM Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its PAVmed (PAVM) stake by 326% in Q1 2026, buying an estimated $4.5K and bringing the position to 622 shares worth $6.31K. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

Tower Research Capital (TRC) first reported a position in PAVM in Q3 2016 and has held it in 26 quarters since. The position peaked at $127K in Q1 2021. 20 funds tracked by Wall St. Rank hold PAVM as of Q1 2026.

  • Tower Research Capital (TRC) held 622 shares of PAVmed worth $6.31K as of Q1 2026.
  • Tower Research Capital (TRC) bought 476 PAVmed shares in Q1 2026, an estimated $4.5K.
  • PAVmed made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4062 holding.
  • Tower Research Capital (TRC) first reported a position in PAVmed in Q3 2016 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s PAVmed position peaked at $127K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held PAVmed as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.